Overview
Aerska, a biotechnology company, has secured $39 million in Series A funding led by EQT Dementia Fund and Age1. The funding will enhance its brain shuttle technology for RNAi therapeutics, targeting neurological disorders and overcoming the blood-brain barrier.
Products
Loading...
Recent Deals
Investors: EQT Dementia Fund, Age1
Aerska, a biotechnology company, has secured $39 million in Series A funding led by EQT Dementia Fund and Age1. The funding will enhance its brain shuttle technology for RNAi therapeutics, targeting neurological disorders and overcoming the blood-brain barrier.